Annovis to Launch 36-Month Extension Study for Buntanetap in Parkinson's Disease

Annovis Bio plans a 36-month extension study to evaluate Buntanetap in Parkinson's disease patients. The study aims to enroll 500 patients across multiple US sites and will include two groups: former participants from earlier Buntanetap studies and patients receiving deep brain stimulation. The study will provide insight into Buntanetap's long-term safety, durability of effect, and potential disease-modifying properties. The extension study supports Annovis' preparations for a future New Drug Application and reflects its commitment to addressing unmet needs in Parkinson's disease.